PCSK9 rs11591147: Understanding the R46L Variant
The rs11591147 variant is a specific genetic change located in the PCSK9 gene. It is widely recognized for its association with lower levels of low-density lipoprotein (LDL) cholesterol and a reduced risk of coronary heart disease.
What each genotype means
Typical cholesterol regulation
This is the most common genotype for this variant, representing the standard genetic sequence at this position. It does not confer the specific protective loss-of-function effect associated with the R46L variant. You should continue to monitor your cholesterol levels through standard clinical screenings as recommended by your healthcare provider.
Carried by the vast majority of individuals in most global populations.
Reduced PCSK9 activity
This genotype includes one copy of the R46L loss-of-function variant, which is associated with lower circulating levels of LDL cholesterol. Research suggests this genetic profile may provide a protective effect against coronary heart disease and certain liver conditions, though the magnitude of this effect can vary by ancestry and sex. Please discuss your overall cardiovascular health and lipid profile with your clinician.
Carried by approximately 1% to 3% of individuals of European ancestry, and is significantly rarer in other populations.
Enhanced PCSK9 loss-of-function
This genotype indicates you carry two copies of the R46L loss-of-function variant. Studies indicate that individuals with this profile typically exhibit more pronounced reductions in LDL cholesterol levels compared to non-carriers. While this is generally associated with a lower risk of coronary heart disease, you should maintain regular communication with your doctor regarding your cardiovascular health and lipid management.
This homozygous genotype is very rare in the general population.
What is rs11591147?
The rs11591147 variant is a single-nucleotide polymorphism (SNP) found within the PCSK9 gene. In scientific literature, this specific variant is frequently referred to as the R46L mutation, which describes a change in the protein's amino acid sequence where arginine is replaced by leucine at position 46. This alteration is classified as a loss-of-function variant, meaning it reduces the normal activity of the protein it encodes. Because it sits in a gene critical for lipid metabolism, researchers have studied it extensively to understand how small changes in our DNA can influence blood chemistry and long-term health outcomes. It is not a disease-causing mutation in the traditional sense; rather, it is a functional variant that shifts the baseline of how the body processes cholesterol.
The Role of the PCSK9 Gene
The PCSK9 gene provides instructions for making a protein that plays a central role in cholesterol homeostasis. This protein binds to LDL receptors on the surface of liver cells, which normally act like sponges to clear LDL cholesterol from the bloodstream. When PCSK9 binds to these receptors, it triggers their degradation, effectively reducing the liver's ability to remove cholesterol from circulation. By producing less active or less efficient PCSK9 protein, the R46L variant (rs11591147) allows more LDL receptors to remain on the surface of liver cells. This leads to more efficient clearance of LDL cholesterol from the blood, resulting in lower circulating levels. Understanding this mechanism has been a major breakthrough in cardiovascular science, as it provided the biological rationale for developing PCSK9 inhibitor medications.
Research and Evidence
The association between rs11591147 and lower LDL cholesterol is supported by robust evidence from numerous population studies and meta-analyses. Carriers of the minor allele consistently show reduced LDL cholesterol levels compared to non-carriers, and this effect has been observed across various age groups. Furthermore, research indicates that this genetic profile is associated with a lower lifetime risk of coronary heart disease. While the cardiovascular benefits are well-documented, some studies have explored whether this variant influences other health outcomes, such as cognitive performance or non-cardiovascular conditions like liver steatosis. Evidence for these secondary associations is more limited or mixed, and some findings remain preliminary. As with all genetic associations, these results represent statistical trends across large populations rather than individual health guarantees.
Interpreting Your Information
Genetic information like the rs11591147 status provides a snapshot of your biological predispositions, but it is only one piece of a much larger puzzle. While this variant is associated with favorable lipid profiles, it does not replace the need for standard medical screenings or healthy lifestyle choices. You cannot use this information to diagnose yourself or to make decisions about stopping or starting medications. If you are concerned about your cholesterol levels or your risk for heart disease, it is essential to discuss your results with a healthcare professional. They can interpret your genetic data in the context of your overall health history, blood work, and other risk factors. Always consult your doctor or pharmacist before making any changes to your health regimen or medication dosing.
How common is this variant?
The rs11591147 minor allele has a frequency of approximately 0.01 to 0.03 in European populations and is generally rarer in other ancestral groups.
Frequently asked questions
Does having the rs11591147 variant mean I will never have high cholesterol?
No. While this variant is associated with lower LDL cholesterol, it does not guarantee healthy levels. Diet, exercise, and other genetic factors also play significant roles in determining your cholesterol levels.
Is rs11591147 the same as taking a PCSK9 inhibitor drug?
They work through the same biological pathway, but they are not the same. The variant is a permanent genetic trait, whereas PCSK9 inhibitor medications are clinical treatments prescribed by doctors to lower cholesterol in specific patients.
Should I get tested for this variant?
Routine testing for this specific SNP is not standard medical practice. If you are interested in your genetic profile, discuss the clinical relevance of such testing with your primary care physician or a genetic counselor.
Are there any downsides to having this variant?
Current research generally views the lower LDL cholesterol associated with this variant as favorable for heart health. While some studies have investigated potential links to other conditions, the evidence is limited and not conclusive.
Sources & further reading
Educational information only, last refreshed 10/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs11591147?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in PCSK9
An upstream regulatory variant in PCSK9 influencing baseline low-density lipoprotein cholesterol levels and clinical response to statin therapy.
Also known as PCSK9 R46L, this loss-of-function variant is associated with significantly lower LDL cholesterol and decreased risk of coronary heart disease.
A "protective" variant that significantly lowers LDL cholesterol and heart risk.